Wearable Sensors For Disease-Specific Data Collection In Clinical Trials - A Pharma Approach (IDTechEx Wearable Europe 2016)

In this talk I will give an overview of our main considerations for choosing and deploying wearable technologies in clinical trials. As an example I will explain how we went about introducing a specific wearable sensor in one of our ongoing Phase II trials, and the impact that this sensor is expected to make in assessing the efficacy of the treatment investigated.

Dr Luis Garcia-Gancedo is the Director of Digital Biomarkers at GlaxoSmithKline (GSK). With a background in Physics and Electronic Engineering, Luis spent a number of years as a Research Associate in the Engineering Department at the University of Cambridge and as a College Lecturer at Newnham College (University of Cambridge) before joining GSK.

Currently he leads the development of a strategic portfolio of novel digital measures of disease progression (digital biomarkers) to support GSK's pipeline of innovative medicines. This includes pioneering new digital tools and data science approaches to investigate these measurements in our therapeutic clinical studies with the aim to collect 'real-world' data that reflects a reasonable approximation of how study participants usually live their lives, ultimately enabling a better understanding of disease manifestation and a better assessment of drug efficacy.

Luis' long-term mission is to use digital technologies to improve the lives of patients, helping them do more, feel better and live longer.

GlaxoSmithKline (GSK) plc is one of the largest pharmaceutical companies in the world. With headquarters in Brentford, London, GSK has 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.